BCL2 and B-cell chronic lymphocytic leukemia: Here, we explored the potential of BDA-366 to kill Bcl-2-dependent CLL and DLBCL cells and scrutinized the mechanism of action, originally proposed to rely on a conformational switch in Bcl-2 by the drug triggering it to expose its BH3 domain and to activate Bax.